In:
Microbiology Spectrum, American Society for Microbiology
Abstract:
Currently, Mycobacterium tuberculosis has exhibited increased drug resistance, leading to ineffective drug treatment in many patients with tuberculosis. Among the anti- Mycobacterium tuberculosis drugs, oxazolidinones have been gradually developed. Contezolid (MRX-I) has been newly developed in China with advantages versus the first oxazolidinone antibiotic approved by the Food and Drug Administration for clinical use, but the anti- M. tuberculosis activity needs to be further clarified. In this study, in vitro activities of MRX-I against M. tuberculosis were tested. The drug susceptibility assays indicated that MRX-I exhibited anti- M. tuberculosis activity comparable to that of linezolid, with an advantage against drug-resistant isolates.
Type of Medium:
Online Resource
ISSN:
2165-0497
DOI:
10.1128/spectrum.04627-22
Language:
English
Publisher:
American Society for Microbiology
Publication Date:
2023
detail.hit.zdb_id:
2807133-5
Permalink